The following is a summary of “Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients ...

VYNE pauses VYN202 psoriasis trial after FDA clinical hold tied to animal toxicity data; separate vitiligo trial remains on ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent ...

Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study. The randomized, ...

Otulfi is FDA-approved for subcutaneous and intravenous formulations to treat the same conditions as Stelara (ustekinumab), ...

Art Garfunkel discusses his experience living with psoriasis as part of Sun Pharma’s I LUV YA for The Long Haul campaign.

In February, VYNE Therapeutics dosed the first subject in a Phase 1b trial evaluating VYN202 in moderate-to-severe plaque psoriasis. The clinical hold does not apply to VYNE’s ongoing Phase 2b ...